CAPRICOR THERAPEUTICS, INC. (CAPR) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $58.11K; Additional Paid in Capital, Common StockUSD $625.88M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-163.54K; Retained Earnings (Accumulated Deficit)USD $-379.55M.
- 2026-03-31: Common Stock, Value, IssuedUSD $57.66K; Additional Paid in Capital, Common StockUSD $617.72M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-253.73K; Retained Earnings (Accumulated Deficit)USD $-338.82M.
- 2025-12-31: Common Stock, Value, IssuedUSD $57.37K; Additional Paid in Capital, Common StockUSD $610.33M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $283.15K; Retained Earnings (Accumulated Deficit)USD $-304.88M.
- 2025-09-30: Common Stock, Value, IssuedUSD $45.72K; Additional Paid in Capital, Common StockUSD $357.68M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $844.12K; Retained Earnings (Accumulated Deficit)USD $-274.71M.
CAPRICOR THERAPEUTICS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Preferred Stock, Value, Issued USD | Additional Paid in Capital USD | Preferred Stock, Value, Outstanding USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $58.11K | $625.88M | $-163.54K | $-379.55M | $246.22M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $57.66K | $617.72M | $-253.73K | $-338.82M | $278.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $57.37K | $610.33M | $283.15K | $-304.88M | $305.79M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $45.72K | $357.68M | $844.12K | $-274.71M | $83.87M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $45.71K | $353.68M | $1.39M | $-250.14M | $104.98M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $45.68K | $350.01M | $1.81M | $-224.23M | $127.65M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $45.58K | $344.22M | $1.03M | $-199.83M | $145.46M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $40.33K | $260.85M | $96.22K | $-192.72M | $68.26M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $31.98K | $191.48M | $154.99K | $-180.16M | $11.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $31.60K | $187.26M | $307.70K | $-169.16M | $18.43M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $31.15K | $181.70M | $235.81K | $-159.37M | $22.60M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $25.86K | $156.68M | $113.21K | $-158.61M | $-1.79M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $25.76K | $154.74M | $179.69K | $-152.21M | $2.73M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $25.25K | $150.93M | $94.99K | $-144.85M | $6.21M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $25.24K | $148.74M | $105.24K | $-137.08M | $11.79M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $24.70K | $144.64M | $122.47K | $-129.36M | $15.43M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $24.34K | $141.67M | $22.83K | $-122.99M | $18.73M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $24.32K | $140.50M | (m) | $-115.88M | $24.64M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $24.18K | $139.40M | $0.00 | $-108.06M | $31.37M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $24.15K | $138.58M | (m) | $-101.87M | $36.74M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $23.00K | $131.30M | (m) | $-97.94M | $33.38M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $22.80K | $129.55M | $0.00 | $-93.19M | $36.38M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $20.58K | $116.22M | $0.00 | $-88.04M | $28.20M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $20.21K | $114.25M | $0.00 | $-83.86M | $30.41M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $19.70K | $111.58M | $0.00 | $-79.95M | $31.65M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $9.19K | $86.05M | $0.00 | $-76.47M | $9.59M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $5.23K | $81.22M | $-757.00 | $-74.38M | $6.84M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $4.17K | $76.48M | $0.00 | $-72.91M | $3.57M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $3.47K | $73.67M | $0.00 | $-71.30M | $2.36M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $33.66K | $72.96M | $0.00 | $-69.26M | $3.74M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $3.14K | $71.34M | $12.39K | $-66.74M | $4.62M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $30.75K | $70.41M | $20.21K | $-63.48M | $6.98M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $29.99K | $68.93M | $18.29K | $-59.34M | $9.63M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $27.97K | $65.71M | $20.33K | $-55.22M | $10.53M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $26.27K | $62.74M | $11.62K | $-51.55M | $11.23M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $25.10K | $59.55M | $8.59K | $-63.85M | $-4.27M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $22.59K | $54.50M | $7.32K | $-61.12M | $-6.59M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $21.40K | $50.42M | $9.71K | $-57.65M | $-7.19M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $21.40K | $49.95M | $3.52K | $-53.98M | $-4.00M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $21.40K | $49.49M | $923.00 | $-49.46M | $49.13K | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $17.95K | $38.99M | $4.78K | $-44.13M | $-5.12M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $17.95K | $38.33M | $3.23K | $-39.44M | $-1.08M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $16.25K | $34.12M | $9.38K | $-35.17M | $-1.03M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $16.25K | $33.72M | $11.95K | $-31.83M | $1.93M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $16.22K | $33.45M | $6.54K | $-28.91M | $4.56M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $16.22K | $33.10M | $-3.94K | $-25.79M | $7.32M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $11.71K | $16.05M | $0.00 | $-22.32M | $-6.25M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | $11.70K | $15.91M | $-1.61K | (m) | $-4.47M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $11.70K | $15.75M | $-874.00 | (m) | $-3.08M | $0.00 | (m) | (m) | (m) | 6 month · $192.21K | (m) | (m) |
| 2014-03-31 | $11.69K | (m) | $-404.00 | (m) | $-1.66M | (m) | $15.64M | $0.00 | (m) | 3 month · $84.54K | (m) | (m) |
| 2013-12-31 | $11.69K | $15.55M | $-980.00 | $-16.10M | $-534.88K | $0.00 | $15.55M | $0.00 | (m) | 12 month · $263.59K | (m) | (m) |
| 2013-09-30 | $43.52K | (m) | (m) | $-48.14M | $-1.57M | $0.00 | $46.53M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | $43.06K | (m) | (m) | $-47.79M | $-1.23M | $0.00 | $46.51M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $43.06K | (m) | (m) | $-47.19M | $-642.66K | $0.00 | $46.51M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $10.35K | (m) | $-21.80K | $-46.71M | $4.89M | $0.00 | $12.11M | (m) | 12 month · $145.79K | 12 month · $332.35K | (m) | 12 month · $-611.90K |
| 2012-09-30 | $43.06K | (m) | (m) | $-46.51M | $27.23K | $0.00 | $46.49M | (m) | 9 month · $145.79K | (m) | (m) | 9 month · $-611.90K |
| 2012-06-30 | $43.06K | (m) | (m) | $-45.94M | $542.25K | (m) | $46.44M | (m) | 6 month · $145.79K | (m) | (m) | 6 month · $-611.90K |
| 2012-03-31 | $39.71K | (m) | (m) | $-45.59M | $230.66K | (m) | $45.78M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $39.71K | (m) | (m) | $-44.81M | $1.66M | $0.00 | $45.61M | (m) | 12 month · $201.43K | 12 month · $15.53K | (m) | (m) |
| 2011-09-30 | $39.71K | (m) | (m) | $-43.15M | $2.37M | (m) | $45.48M | (m) | 9 month · $201.43K | (m) | (m) | (m) |
| 2011-06-30 | $39.71K | (m) | (m) | $-42.01M | $3.27M | (m) | $45.23M | (m) | 6 month · $201.43K | (m) | (m) | (m) |
| 2010-12-31 | $34.63K | (m) | (m) | $-39.93M | $1.79M | (m) | $42.49M | (m) | 12 month · $91.16K | 12 month · $24.16K | (m) | (m) |
| 2009-12-31 | (m) | (m) | (m) | (m) | $911.77K | (m) | (m) | (m) | 12 month · $282.77K | 12 month · $8.25K | (m) | (m) |
| 2008-12-31 | (m) | (m) | (m) | (m) | $252.55K | (m) | (m) | (m) | (m) | 12 month · $16.42K | (m) | (m) |
| 2007-12-31 | (m) | (m) | (m) | (m) | $863.17K | (m) | (m) | (m) | 12 month · $102.00K | 12 month · $5.82K | 12 month · $483.46K | (m) |
| 2006-12-31 | (m) | (m) | (m) | (m) | $1.84M | (m) | (m) | (m) | (m) | 12 month · $10.00K | (m) | (m) |
| 2005-12-31 | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2005-07-04 | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |